Reported about 1 year ago
The Federal Trade Commission (FTC) released an interim report criticizing pharmacy benefit managers (PBMs) for having significant control over patients' access to and affordability of prescription drugs, impacting drug availability and pricing. The report highlights unfair contractual terms by PBMs that harm independent pharmacies. The top three PBMs processed around 80% of the 6.6 billion prescriptions dispensed in the US in 2023. While the FTC's findings were disputed by Cigna, concerns about escalating drug prices and lack of transparency were validated by the report, prompting further investigation and response from the FTC.
Source: YAHOO